Remove 2013 Remove Dosage Remove Drug Pricing
article thumbnail

ProxsysRx’s MedServRx: The Prescription-Drug Advantage For Patients And Their Providers

Proxsys Rx

As the study’s authors noted, “Overpayments are more likely on claims for generic versus brand drugs (28% vs. 6%), but the average size of the overpayment on generic claims is smaller ($7.32 In 2013, total overpayments amounted to $135 million in our sample, or $10.51 vs. $13.46). per covered life.”

article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 23 April 2013. Patents are often described as the ‘lifeblood’ of pharmaceutical companies.